Unitl 2005 dba Silico Insights, Inc, Nuvera Biosciences, Inc., a molecular diagnostics company, developing diagnostic solutions for oncology diseases. Launched out of University of Texas M. D. Anderson Cancer Center based on pioneering multi-gene profiling in cancer treatment trials, the company focuses on developing breast cancer genomic assays. Products include aromatase inhibitors, anthracycline-based chemotherapy, and biomarkers for breast cancer patients. Nuvera Biosciences has developed a novel, proprietary research and computational platform that enables a complete understanding of data dependencies and inter-relationships. The technology platform has the capability to study and connect disparate physiological and clinical events and establish key, quantitative dependencies across the entire drug discovery and development pipeline. In drug discovery, validation of key pathway elements using tissue-based approaches delivers new avenues for diagnostic products and screening tests for drug candidates. The Company has also built a unique portfolio within cancer and inflammation-based diseases through its collaborations and projects that consists of methodologies for marker characterization and validation. Some of these ongoing developments are now focused on potential commercialization of these markers as diagnostic and drug tests in specific cancer areas
